Ethyl loflazepate


Concise Prescribing Info
Indications/Uses
Anxiety.
Dosage/Direction for Use
Adult : PO 1-3 mg/day.
Dosage Details
Oral
Short-term management of anxiety
Adult: 1-3 mg/day in single or divided doses.
Contraindications
Preexisting CNS depression or coma, respiratory depression, acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; not indicated for chronic psychosis, phobic or obsessional states; may precipitate suicide or aggressive behaviour, not used alone to treat depression or anxiety associated with depression; glaucoma.
Special Precautions
Chronic pulmonary insufficiency; elderly or debilitated patients; muscle weakness, impaired liver or kidney function; drowsiness may affect skilled tasks; monitor cardio-respiratory function when used for deep sedation; patients with personality disorders or organic brain changes; pregnancy, lactation; history of alcohol or drug addiction due to risk of dependence. Respiratory depression and hypotension may occur with parenteral admin.
Adverse Reactions
Drowsiness, sedation, muscle weakness and ataxia; less frequently vertigo, headache, confusion, depression, slurred speech, changes in libido, tremor, visual disturbances, urinary retention, GI disturbances, changes in salivation and amnesia; rarely, jaundice, blood disorders and hypersensitivity reactions; pain and thrombophlebitis; raised liver enzyme values; paradoxical excitation.
Drug Interactions
Enhanced sedation or respiratory and CV depression with drugs that have CNS depressant properties e.g. antidepressants, antihistamines, antipsychotics, general anesthetics, other hypnotics or sedatives, opioid analgesics and cisapride.
Potentially Fatal: Drugs which alter the hepatic microsomal enzymes.
Food Interaction
Alcohol enhances sedation or respiratory and CV depression effects.
Action
Description: Ethyl loflazepate has general properties similar to diazepam and a long-acting benzodiazepine derivative used in the short-term treatment of anxiety disorders.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Ethyl loflazepate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in